Inmaculada González-Molero

Dr. Inmaculada González-Molero

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2013 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
IGInmaculada González-Molero
Inmaculada González-Molero
Gemma Rojo-MartinezGemma Rojo-Martinez
Gemma Rojo-Martinez
SMSonsoles Morcillo
Sonsoles Morcillo
CGC Gutierrez
C Gutierrez
ERE Rubio
E Rubio
FSF Soriguer
F Soriguer

22 December 2010 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
IGInmaculada González-Molero
Inmaculada González-Molero
SMSonsoles Morcillo
Sonsoles Morcillo
SVS Valdés
S Valdés
VPV Pérez-Valero
V Pérez-Valero
PBP Botas
P Botas
FSF Soriguer
F Soriguer

1 August 2012 in Clinical Nutrition
Verified
Journal Article
Closed access
IGInmaculada González-Molero
Inmaculada González-Molero
Gemma Rojo-MartinezGemma Rojo-Martinez
Gemma Rojo-Martinez
SMSonsoles Morcillo
Sonsoles Morcillo
Carolina Gutiérrez RepisoCarolina Gutiérrez Repiso
Carolina Gutiérrez Repiso
ERElehazara Rubio-Martín
Elehazara Rubio-Martín
FSFederico Soriguer
Federico Soriguer

21 August 2012 in Journal of Telemedicine and Telecare
Verified
Journal Article
Closed access
IGInmaculada González-Molero
Inmaculada González-Molero
MDMarta Domínguez-López
Marta Domínguez-López
MGMercedes Guerrero
Mercedes Guerrero
MCMónica Carreira
Mónica Carreira
FCFelix Caballero
Felix Caballero
FSFederico Soriguer
Federico Soriguer
We evaluated a telemedicine system in patients with type 1 diabetes who had optimized treatment with an insulin pump and a real-time continuous glucose monitoring system. We conducted a prospective, one-year study of 15 subjects. Three medical visits took place: pre-baseline, baseline and at 6 months. Each month the subjects transmitted information from the glucose meter, glucose sensor and insulin pump. We adjusted the treatment and returned the information by email. We evaluated psychological and metabolic variables, including HbA1c, hypoglycaemia, hyperglycaemia and glucose variability. At baseline the mean age of the subjects was 40 years and the mean duration of diabetes was 22 years. There was a significant reduction in HbA1c (7.50 to 6.97%) at 6 months, a significant increase in the number of self-monitoring blood glucose checks per day (5.2 to 6.2), and significant improvements in variability: MODD, mean of daily difference (67 to 53) and MAGE, mean amplitude of glycaemic excursions (136 to 102). There were significant improvements in quality of life (92 to 87), satisfaction with the treatment (34 to 32) and less fear of hypoglycaemia (36 to 32). Adult subjects with type 1 diabetes on treatment with a continuous insulin infusion system and a real time glucose sensor and who have acceptable metabolic control and optimized treatment can benefit from the addition of a telemetry system to their usual outpatient follow-up.

1 March 2016 in Medicina Clinica
Verified
Journal Article
Closed access
MRMaría Soledad Ruiz-De-Adana
María Soledad Ruiz-De-Adana
MDMarta-Elena Dominguez-Lopez
Marta-Elena Dominguez-Lopez
IGInmaculada González-Molero
Inmaculada González-Molero
AMAlberto Machado
Alberto Machado
VMVictor Martin
Victor Martin
Gemma Rojo-MartinezGemma Rojo-Martinez
Gemma Rojo-Martinez

25 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Marta Araujo-CastroMarta Araujo-Castro
Marta Araujo-Castro
RGRogelio García-Centeno
Rogelio García-Centeno
LGLaura González
Laura González
FHFelicia Alexandra Hanzu
Felicia Alexandra Hanzu
AAAida Orois Anon
Aida Orois Anon
ASAlfonso Soto-Moreno
Alfonso Soto-Moreno
Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed.